Coverage
-
February 01, 2019
Allergan Inc.'s aggressive bid to block sales of lower-cost compounded drugs has ended with a compounder's agreement to tell customers that its products aren't approved by the U.S. Food and Drug Administration.
4 other articles on this case.
View all »